Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

NCT02502266 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02502266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 3, 2016
Completion date
March 4, 2027
Enrollment
582 (actual)
Sites
398

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma